Zealand Pharma announced Phase 2 topline results for the investigational amylin analogue petrelintide. Review the week-28 weight and HbA1c clinical findings.
On October 7, 2026, Zealand Pharma announced topline results from its randomized, double-blind Phase 2 ZUPREME-2 trial. This clinical study tested a once-weekly investigational medication called petrelintide against a placebo. The trial enrolled 220 adult participants who have overweight or obesity and type 2 diabetes. These preliminary findings offer an initial look at an investigational approach to metabolic health.
Successful body composition changes require addressing the physiological factors that drive appetite, rather than relying on willpower alone. Petrelintide is an investigational, long-acting human amylin analogue designed to influence these very factors. Amylin is a naturally occurring hormone that the body uses to help regulate digestion and communicate satiety to the brain. By mimicking this natural hormone, the medication attempts to modify the underlying biological pathways that control hunger and energy balance.
Many prominent weight-loss treatments currently focus on incretin pathways to achieve metabolic improvements. This investigational medicine takes a slightly different route by targeting the amylin system instead. Zealand Pharma administers this treatment via a once-weekly subcutaneous injection for consistent dosing. The company stated it is developing the medicine with Roche for chronic weight management.
The clinical development plan tests this medication through multiple therapeutic approaches. Zealand Pharma is evaluating it as a standalone treatment for metabolic conditions. Additionally, the company is testing it in combination with Roche’s GLP-1/GIP receptor dual agonist enicepatide. This dual strategy reflects a growing trend in medical research to target multiple hormonal systems simultaneously.
Understanding the biology of weight regain highlights why researchers continue searching for new treatment pathways. Single-hormone treatments work well for many patients, but they do not address every metabolic complication. By studying amylin analogues, scientists hope to provide alternative options for individuals who struggle with existing medications. These scientific advancements help expand the toolbox for comprehensive clinical care.
Media coverage of new pharmaceutical developments frequently highlights the highest available percentages without necessary context. It is essential to recognize that the ZUPREME-2 release only provides topline Phase 2 findings. Zealand Pharma confirmed that the complete dataset will be presented at an upcoming scientific conference. Until those detailed findings are published, the public announcement remains an incomplete picture of the medication's performance.
The current release provides broad data ranges but does not map each specific result to an exact dose. Furthermore, the topline announcement does not include rigorous statistical measures like p-values or confidence intervals. This lack of granularity makes it difficult to fully evaluate the clinical significance of the early results. Patients should wait for peer-reviewed publications before drawing conclusions about this investigational therapy.
Industry observers had mixed reactions to the specific metabolic markers reported in the trial. BioSpace reported that analysts were underwhelmed by the blood-sugar numbers, despite viewing the weight-loss data as intriguing. Fierce Biotech similarly framed the HbA1c results as less favorable than those of current market competitors. These financial and analyst perspectives emphasize the high expectations placed on modern metabolic medications.
However, Fierce Biotech correctly noted the strict limitations of comparing different clinical trials directly. ZUPREME-2 compared petrelintide to a simple placebo, rather than testing it against another active drug. This trial structure means the preliminary findings cannot establish comparative effectiveness against proven treatments. Any assumptions about how this medicine stacks up against existing options remain purely speculative at this stage.
The reported weight change was also measured at week 28 of the clinical trial. This duration is relatively short for a chronic weight management intervention. These specific results do not establish how much weight loss patients would maintain over longer treatment periods. A separate Phase 2 trial called ZUPREME-1 did report week-42 reductions of up to 10.2 percent, but that involved participants without type 2 diabetes.
The ZUPREME-2 trial tracked specific shifts in body weight and glycemic control over the 28-week period. Participants entered the study with a mean baseline body mass index of 36.3 kg/m². These adults also presented with a mean baseline HbA1c of 8.0 percent. To manage tolerability, treatment doses were systematically escalated every fourth week during the early stages of the trial.
The topline results highlighted noticeable differences between the active treatment arms and the placebo group. At week 28, mean weight loss across the three petrelintide groups ranged from 7.4 percent to 9.2 percent. In contrast, participants receiving the placebo experienced an average weight loss of 2.0 percent. Zealand Pharma noted that the trial successfully met its primary endpoint for these initial efficacy measurements.
The researchers also monitored blood sugar changes, which are vital for individuals living with type 2 diabetes. Zealand reported placebo-adjusted HbA1c reductions of 0.61 to 0.88 percentage points across the treatment arms. The company announcement also highlighted a maximum absolute reduction of 0.65 percentage points with the active medication. Meanwhile, the placebo group saw a slight 0.23-point increase in their HbA1c levels over the same timeframe.
For anyone following developments in weight loss and metabolic health, medication tolerability is a major priority. Discontinuation due to gastrointestinal adverse events was just 1.9 percent among petrelintide recipients. This metric was notably similar to the 1.7 percent discontinuation rate observed among placebo recipients. The company stated that no unexpected safety signals appeared during this phase of testing.
According to the report, most of the gastrointestinal events were mild and happened during the initial dose escalation. These safety observations are encouraging for researchers preparing for larger clinical applications. However, the topline release does not offer a complete, detailed breakdown of all adverse events. As with any investigational drug, managing potential side effects remains a central focus for future clinical validation.
These Phase 2 findings provide a valuable glimpse into an alternative biological approach to metabolic care. However, this is merely a research update, rather than a sign that petrelintide is ready for immediate clinical use. The practical takeaway is to follow the complete trial data as it emerges from the scientific community. Patients should never alter their current treatment strategies based on preliminary, placebo-controlled announcements.
To gather more definitive evidence, Zealand Pharma and Roche have already started a comprehensive Phase 3a program. This advanced clinical phase includes three separate trials named ZUPREME-3, ZUPREME-4, and ZUPREME-5. The companies expect to enroll approximately 7,000 participants across these massive research initiatives. This scale of testing is required to confirm the safety and efficacy observed in earlier studies.
The upcoming trials will evaluate the medication across much broader and more complex patient groups. Researchers will include people who have overweight or obesity, along with those managing established cardiovascular disease. Tracking health outcomes across diverse populations is a critical requirement for modern pharmaceutical approval. These extended studies will eventually clarify if this medication offers a viable strategy for lifelong health.
Until those extensive trials conclude, the focus for patients should remain on accessible and proven interventions. Managing metabolic health requires sustainable habits alongside medication, comprehensive medical guidance, and realistic long-term planning. The next few years will reveal whether amylin analogues can reliably support these critical lifestyle changes. The medical community awaits the full scientific presentation to better understand this evolving landscape.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
